Notable Partnership Boosts Helius Medical (HSDT) Stock
Notable Partnership Boosts Helius Medical (HSDT) Stock
Helius Medical Technologies, Inc. (NASDAQ: HSDT) is witnessing a notable surge of 22.83% during the pre-market trading session, currently valued at $6.95 per share. This positive momentum in HSDT shares can be directly attributed to the recent announcement of a strategic partnership.
Helius Medical Technologies, Inc.（納斯達克股票代碼：HSDT）在盤前交易時段顯著上漲了22.83％，目前估值爲每股6.95美元。HSDT股票的這種積極勢頭可以直接歸因於最近宣佈的戰略合作伙伴關係。
Today, Helius Medical (HSDT) and Lovell Government Services announced their partnership. Through this partnership, HSDT will be able to provide government healthcare systems with access to its Portable Neuromodulation Stimulator ("PoNS"). PoNS can be used to treat gait impairments in people with mild to moderate symptoms of multiple sclerosis (MS) in conjunction with physical therapy.
今天，Helius Medical（HSDT）和洛弗爾政府服務公司宣佈了合作伙伴關係。通過這種夥伴關係，HSDT將能夠爲政府醫療保健系統提供其便攜式神經調節刺激器（“PoNs”）的使用權限。PonS 可結合物理療法治療有輕度至中度多發性硬化症（MS）症狀的人的步態障礙。
Helius Medical and Lovell's partnership will make the revolutionary point-of-care technology (PONS) more widely available. Through its Multiple Sclerosis Centers of Excellence, the Department of Veterans Affairs (VA) is dedicated for enhancing the quality of life for veterans who suffer from multiple sclerosis.
Helius Medical和Lovell的合作將使革命性的即時醫療技術（PONS）更廣泛地可用。退伍軍人事務部（VA）通過其多發性硬化症卓越中心，致力於改善患有多發性硬化症的退伍軍人的生活質量。
After receiving PoNS Therapy for 14 weeks, 100% of MS patients had clinically significant improvements in their gait, according to a real-world efficacy study. PoNS has the potential to completely transform the way that veterans and their families are treated, as the VA receives reports on over 28,000 MS cases each year.
根據一項現實世界的療效研究，在接受PonS治療14周後，100％的多發性硬化症患者的步態有了臨床上的顯著改善。PONs有可能徹底改變退伍軍人及其家屬的治療方式，因爲弗吉尼亞州每年收到超過28,000例多發性硬化症病例的報告。
The VA, with the most integrated healthcare system in the country, is committed to provide lifelong comprehensive treatment to veterans with multiple sclerosis. Veterans should have access to the most cutting-edge and effective resources available since they have made important contributions to their nation.
弗吉尼亞州擁有全國最完整的醫療體系，致力於爲患有多發性硬化症的退伍軍人提供終身綜合治療。退伍軍人應該有機會獲得最前沿和最有效的可用資源，因爲他們爲國家做出了重要貢獻。
Recently, Helius Medical spotlighted the personal narrative of Kevin Byrne, a retired U.S. veteran grappling with MS since 1999. Gait impairments had robbed him of cherished experiences with his 13-year-old daughter, yet PoNS Therapy aided in enhancing his walking abilities, including speed, endurance, and distance.
最近，Helius Medical聚焦了凱文·伯恩的個人故事，他是一位退休的美國退伍軍人，自1999年以來一直在努力應對多發性硬化症。步態障礙使他失去了與13歲女兒在一起的寶貴經歷，但PonS療法幫助他增強了行走能力，包括速度、耐力和距離。
Following treatment with PoNS, he was able to accompany his daughter to New York City, where they relished strolling the streets and attending Broadway shows—experiences he believed were forever out of reach. While clinical data underscores the effectiveness of PoNS Therapy, firsthand testimonials such as Captain Byrne's serve as the most rewarding validation of its impact.
在接受PonS治療後，他得以陪同女兒去紐約市，在那裏他們喜歡在街上漫步和參加百老匯演出——他認爲這種經歷永遠遙不可及。儘管臨床數據強調了PonS療法的有效性，但諸如伯恩上尉之類的第一手證詞是對其影響的最有意義的驗證。
譯文內容由第三人軟體翻譯。